Net Loss per Share Attributable to Common Stock - Schedule of Outstanding Shares of Common Stock Equivalents (Details) - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Stock options | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Common stock equivalents (in shares) | 43,996 | 147,707 |
| Non-vested restricted stock awards | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Common stock equivalents (in shares) | 100,206 | 362,561 |
| Non-vested restricted stock units | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Common stock equivalents (in shares) | 2,048,993 | 2,533,310 |
| Common stock warrants | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Common stock equivalents (in shares) | 0 | 240,100 |
| Convertible debt | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Common stock equivalents (in shares) | 1,759,804 | 1,759,804 |